SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-22-010256
Filing Date
2022-10-04
Accepted
2022-10-04 06:01:49
Documents
13
Period of Report
2022-10-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_100322.htm   iXBRL 8-K 28682
2 PRESS RELEASE ex99-1.htm EX-99.1 12865
  Complete submission text file 0001387131-22-010256.txt   221537

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE admp-20221003.xsd EX-101.SCH 3266
4 XBRL LABEL FILE admp-20221003_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE admp-20221003_pre.xml EX-101.PRE 22385
7 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_100322_htm.xml XML 3589
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 221289652
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences